462127-22-6

Basic information

• Product Name: 4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-carboxylate tert-butyl ester
• Synonyms: 4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-carboxylate tert-butyl ester
• CAS NO: 462127-22-6
• Molecular Weight: 343.346
• Mol File: 462127-22-6.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-carboxylate tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-carboxylate tert-butyl ester(462127-22-6)
• EPA Substance Registry System: 4-(4-(trifluoromethoxy)phenyl)-5,6-dihydropyridin-1(2H)-carboxylate tert-butyl ester(462127-22-6)

Safety Data

• Hazardous Substances Data: 462127-22-6(Hazardous Substances Data)

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 459819-54-6 4-(4-(trifluoromethoxy)phenyl)piperidine-1-formic acid tert-butyl ester 
• 180160-91-2 4-(4-(trifluoromethoxy)phenyl)piperidine 
• 1613627-57-8 4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzonitrile 
• 1426520-69-5 (4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methanamine 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents

A series of pyrazolo[1,5-a]pyridine-3-carboxamide derivatives were designed and synthesized as new anti-Mycobacterium tuberculosis (Mtb) agents. The compounds exhibit promising in vitro potency with nanomolar MIC values against the drug susceptive H37Rv s

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

Pyrazolo[1, 5-a]pyridine compound and use thereof

The invention discloses a pyrazolo[1, 5-a]pyridine compound with the structure characteristic shown in the formula (I) or its pharmaceutically acceptable salt, stereoisomer or prodrug molecule and a use thereof. The compound has good in-vitro anti-tubercle bacillus activity, has the minimal inhibitory concentration (MIC) less than 0.1 micrograms per milliliter and partial MIC of 0.01 micrograms per milliliter and has strong inhibition effects on a clinically sorted multi-drug-resistant tuberculosis (MDR-TB) strain. In an in-vivo experiment, at a dosage of 20mg/kg/d, the pyrazolo[1, 5-a]pyridine compound can effectively eliminate H37Ra infection in a mouse and is a novel anti-tuberculosis compound.

Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.